Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/ijms20061328
Keywords
oral submucous fibrosis; LINC00974; arecoline; myofibroblasts; TGF-beta signaling
Funding
- Chung Shan Medical University and Changhua Christian Hospital [CSMU-CCH-107-02]
- Chung Shan Medical University Hospital [CSH-2018-C-017]
- Ministry of Science and Technology in Taiwan [MOST 108-2314-B-040 -003]
Ask authors/readers for more resources
Oral submucous fibrosis (OSF) is an oral precancerous condition associated with the habit of areca nut chewing and the TGF-beta pathway. Currently, there is no curative treatment to completely heal OSF, and it is imperative to alleviate patients' symptoms and prevent it from undergoing malignant transformation. Arctigenin, a lignan extracted from Arctium lappa, has been reported to have a variety of pharmacological activities, including anti-fibrosis. In the present study, we examined the effect of arctigenin on the cell proliferation of buccal mucosal fibroblasts (BMFs) and fibrotic BMFs (fBMFs), followed by assessment of myofibroblast activities. We found that arctigenin was able to abolish the arecoline-induced collagen gel contractility, migration, invasion, and wound healing capacities of BMFs and downregulate the myofibroblast characteristics of fBMFs in a dose-dependent manner. Most importantly, the production of TGF-beta in fBMFs was reduced after exposure to arctigenin, along with the suppression of p-Smad2, alpha-smooth muscle actin, and type I collagen A1. In addition, arctigenin was shown to diminish the expression of LINC00974, which has been proven to activate TGF-beta/Smad signaling for oral fibrogenesis. Taken together, we demonstrated that arctigenin may act as a suitable adjunct therapy for OSF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available